A RESPONSE to ruxolitinib: update on 4-year trial follow-up

Jean-Jacques Kiladjian

An exciting update on the 4-year follow-up of the RESPONSE Trial (NCT01243944) was given by Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. The RESPONSE trial compared the efficacy and safety of ruxolitinib vs. the best available therapy in patients with hydroxyurea-intolerant/resistant polycythemia vera (PV). Now, after conducting a 4-year follow-up on the study, Prof. Kiladijan discusses the results and the next steps.

Share this video  
Similar topics
Related videos
2:38
Heritability of MPNs
Valeria Santini
1:33
MYMPN: a patient registry removing bias from MPN research
Ruben Mesa
1:30
Yoga as a non-pharmacological intervention for MPNs
Ruben Mesa
1:54
Current treatment landscape in classical MPNs
Ruben Mesa
1:13
MPN therapies: the current landscape
Claire Harrison
Myeloproliferative Neoplasms, Polycythemia Vera
Hydroxyurea, Ruxolitinib
RESPONSE
ASH 2017
Interview
More from Jean-Jacques Kiladjian
The importance of patient registries
PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs
CONTI-PV: a 2-year follow-up of interferon product AOP2014
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals